Oral Wegovy Fastest Drug Launch
The launch of oral Wegovy (semaglutide) pills in January has been hailed as the "fastest drug launch ever," potentially reshaping weight management by expanding access beyond injections. Pills are expected to drive further innovation in the intersection of weight loss, metabolism, and medical science.
- In its first week ending January 9, 2026, oral Wegovy prescriptions reached nearly 3,100, significantly outpacing the launch week of its competitor, Eli Lilly's injectable Zepbound, which had approximately 1,300 new patients. By late January, weekly prescriptions for the Wegovy pill had grown to 50,000. - The U.S. Food and Drug Administration (FDA) approved the Wegovy pill on December 22, 2025, making it the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. The approval was based on the OASIS 4 trial, which showed an average weight loss of 16.6%, comparable to the injectable version. - The pill formulation is made possible by a co-formulation with an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). SNAC protects the active ingredient, semaglutide, from stomach acid and helps it get absorbed into the bloodstream. - The injectable version of Wegovy generated $7.1 billion in global sales for its manufacturer, Novo Nordisk, in 2025. The company's total revenue from its GLP-1 drugs, including Ozempic for diabetes, reached $21.9 billion in the same year. - The oral version of Wegovy must be taken on an empty stomach 30 minutes before the first food, beverage, or other oral medications of the day. - Competition in the oral weight-loss drug market is expected to intensify, with Eli Lilly's drug, orforglipron, potentially receiving FDA approval in 2026. Unlike oral Wegovy, orforglipron is a small molecule that does not require an absorption enhancer and can be taken without food or water restrictions. - Other pharmaceutical companies, including Viking Therapeutics and Amgen, are also developing oral and injectable weight-loss drugs with different mechanisms of action, aiming to enter the lucrative market currently dominated by Novo Nordisk and Eli Lilly.
